Results 161 to 170 of about 169,930 (262)
Salivary biomarkers in sleep‐related disorders
Abstract The exploration of salivary biomarkers has emerged as a promising avenue in the diagnosis and management of sleep‐related disorders, such as obstructive sleep apnea (OSA), insomnia, and sleep deprivation. Saliva is a noninvasive biofluid that contains a wealth of biological markers, reflecting both local and systemic physiological changes ...
Chuan Xiang Li +9 more
wiley +1 more source
The role of mucosal immune dysregulation in the pathogenesis of immunoglobulin A nephropathy. [PDF]
Ohyama Y +4 more
europepmc +1 more source
This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta +8 more
wiley +1 more source
Structural promiscuity in the human circulatory IgA1 clonal repertoire. [PDF]
Rolland AD +4 more
europepmc +1 more source
LC‐OCT of Dermatitis Herpetiformis
JEADV Clinical Practice, EarlyView.
Daniele Omar Traini, Gerardo Palmisano
wiley +1 more source
Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis
ABSTRACT Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma ...
Zhe Wang +3 more
wiley +1 more source
Celiac Disease Presenting With Erythema Nodosum in a Child: Case Report and Review of the Literature. [PDF]
Pavlovic M, Berenji K, Rokvic Z.
europepmc +1 more source
A Painful Purpuric Rash in a Febrile Smoker
JEADV Clinical Practice, EarlyView.
Eugerta Dilka +3 more
wiley +1 more source
ABSTRACT Upadacitinib (UPA) is a selective Janus kinase 1 inhibitor that improves moderate‐to‐severe atopic dermatitis, but real‐world strategies to maintain remission after response remain unclear. We conducted a multicenter retrospective study in Japan of 219 patients aged ≥ 12 years who achieved protocol‐defined remission, defined as Investigator's ...
Yuichiro Tsunemi +3 more
wiley +1 more source

